A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ≥18 years in age, male or female.
• Relapsed/refractory AML patients.
• ECOG performance status score is 0 to 2.
• Life expectancy of at least 3 months.
• Adequate bone marrow and good organ function.
• Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document.
Locations
Other Locations
China
Hematology Hospital of the Chinese Academy of Medical Sciences
RECRUITING
Tianjin
Contact Information
Primary
Yu meng Zhou
yumeng_zhou@163.com
86-025-85109999
Time Frame
Start Date: 2023-08-07
Estimated Completion Date: 2026-08
Participants
Target number of participants: 72
Treatments
Experimental: NTQ2494
For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).
Related Therapeutic Areas
Sponsors
Leads: Nanjing Chia-tai Tianqing Pharmaceutical